English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Recent studies have shown that bone marrow mononuclear cell (BM-MNC) therapy improves exercise capacity in patients with more advanced chronic heart failure (HF) [1]. However, few studies have explored the safety profile and efficacy of allogeneic umbilical cord blood mononuclear cells (CB-MNCs) administered intravenously to patients with CHF. The umbilical cord blood was taken from healthy full-term and naturally delivered newborns after written informed consent were obtained from their mothers and other family members. The study protocol was reviewed and approved by the hospital review board and ethics committee of Taizhou People’s Hospital (Taizhou, China). Also, the study protocol was performed in compliance with current Good Clinical Practice standards.

Left ventricular improvement due to allogeneic CB-MNCs transplantation in a chronic heart failure six-years after myocardial infarction